NEW YORK (GenomeWeb News) — Ingenuity Systems today said it has extended a licensing agreement with Merck that allows the drug maker to continue using its Ingenuity Pathways Analysis Software.
Under the terms of the “multi-year” agreement, Merck will continue to use the IPA software for research in “multiple therapeutic areas,” Ingenuity said.
The original agreement was signed in 2004, but the company did not say when the extended licensing contract will expire.
Ingenuity said the software supports biomarker target identification and validation, predictive toxicology, and pharmacogenomics on “all high throughput analysis platforms.”
Financial terms of the agreement were not released.